ImClone Systems, Inc. (IMCL)

mdriver78 (< 20) Submitted: 6/02/08 5:33 AM : Start Price: $40.50 IMCL Score: 98.19

From a Reuters report, "researchers claim another step closer to the "Holy Grail" of so-called personalized medicine, whereby information about a patient's genotype is used to select medication.





The study, looking at a subset of subjects from a larger clinical trial, found that colon cancer patients whose tumors contained the normal, or wild type, KRAS gene could gain a significant benefit from Erbitux treatment, while those with a mutated KRAS gene saw no benefit from the ImClone drug."





The results, presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago, demonstrate that a genetic test could help rule out roughly one-third of patients whose cancer would not be helped by the expensive biotechnology drug, as well as identify those most likely to benefit.





The results present a socially responsible Company looking to target patients that will be helped by the Erbitux Drug and not just looking at the bottom line which is Company I would like to be invested in.

Report this Post Replies: 0 | Reply